Non Small Cell Lung Cancer (Squamous or Non Squamous)
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung
Prevalence
6.0 / 100K
Incidence
8.0 / 100K/yr
3 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Phase 2(2)
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| eik1001 | Eikon Therapeutics Inc. (EIKN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Non Small Cell Lung Cancer (Squamous or Non Squamous)?
BioSniper tracks 3 drugs in development for Non Small Cell Lung Cancer (Squamous or Non Squamous) across 2 companies.
How many clinical trials target Non Small Cell Lung Cancer (Squamous or Non Squamous)?
There are 2 clinical trials targeting Non Small Cell Lung Cancer (Squamous or Non Squamous) tracked by BioSniper.
What is the prevalence of Non Small Cell Lung Cancer (Squamous or Non Squamous)?
The estimated prevalence of Non Small Cell Lung Cancer (Squamous or Non Squamous) is approximately 6.0 per 100,000 population.
Deep-dive into Non Small Cell Lung Cancer (Squamous or Non Squamous)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis